CONTER, VALENTINO
 Distribuzione geografica
Continente #
NA - Nord America 2.842
EU - Europa 1.287
AS - Asia 671
SA - Sud America 51
Continente sconosciuto - Info sul continente non disponibili 8
AF - Africa 5
OC - Oceania 3
Totale 4.867
Nazione #
US - Stati Uniti d'America 2.812
SG - Singapore 316
IT - Italia 258
SE - Svezia 213
DE - Germania 204
CN - Cina 193
RU - Federazione Russa 172
IE - Irlanda 146
HK - Hong Kong 57
GB - Regno Unito 54
AT - Austria 50
UA - Ucraina 41
BR - Brasile 35
FR - Francia 35
VN - Vietnam 33
FI - Finlandia 32
CA - Canada 26
ID - Indonesia 22
DK - Danimarca 19
TR - Turchia 17
BE - Belgio 13
IN - India 10
NL - Olanda 10
AR - Argentina 9
PL - Polonia 7
EU - Europa 6
PT - Portogallo 6
GR - Grecia 5
KR - Corea 5
PE - Perù 5
ES - Italia 4
RO - Romania 4
AU - Australia 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
GT - Guatemala 3
NO - Norvegia 3
BD - Bangladesh 2
BG - Bulgaria 2
CY - Cipro 2
EC - Ecuador 2
EG - Egitto 2
IQ - Iraq 2
IR - Iran 2
PH - Filippine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
DZ - Algeria 1
IL - Israele 1
JP - Giappone 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MX - Messico 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 4.867
Città #
Ann Arbor 677
Fairfield 242
Chandler 219
Singapore 208
Woodbridge 171
Wilmington 168
Ashburn 156
Dublin 145
Frankfurt am Main 142
Houston 137
Seattle 107
Cambridge 89
Dearborn 86
New York 83
Milan 77
Santa Clara 66
Hong Kong 57
Princeton 52
Vienna 44
Jacksonville 43
Nanjing 32
Altamura 28
Lawrence 26
Shanghai 24
Jakarta 22
Rome 22
Helsinki 21
Grafing 20
Dong Ket 15
Guangzhou 15
San Diego 15
Beijing 14
Boardman 13
Brussels 10
London 10
Nanchang 10
Paris 9
Toronto 9
Council Bluffs 8
Lissone 8
Moscow 8
Sulmona 8
Andover 7
Kunming 7
Los Angeles 7
Mountain View 7
Perugia 7
Shenyang 7
Chicago 6
Lachine 6
Ottawa 6
Bonndorf 5
Edmonton 5
Lisbon 5
Monza 5
Zhengzhou 5
Athens 4
Belo Horizonte 4
Besana In Brianza 4
Bologna 4
Changsha 4
Hangzhou 4
Jinan 4
Nuremberg 4
São Paulo 4
Warsaw 4
Buenos Aires 3
Catania 3
Como 3
Desio 3
Edinburgh 3
Fuzhou 3
Gaithersburg 3
Gap 3
Hebei 3
Hefei 3
Leawood 3
Lima 3
Norwalk 3
Oslo 3
Pune 3
Redmond 3
Rho 3
Tianjin 3
Turin 3
Brasília 2
Brno 2
Campobasso 2
Cedar Knolls 2
Cinisello Balsamo 2
Copperas Cove 2
Daejeon 2
El Salvador 2
Este 2
Fort Worth 2
Istanbul 2
Kraków 2
Merate 2
Naples 2
Nicosia 2
Totale 3.528
Nome #
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 297
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 252
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study 249
Oral nutritional supplementation in children treated for cancer in low- and middle-income countries is feasible and effective: The experience of the children's hospital manuel de jesus rivera "la mascota" in Nicaragua 237
Autologous Purified Peripheral Blood Stem Cell Transplantation Compare to Chemotherapy in Childhood Acute Lymphoblastic Leukemia after Low-Risk Relapse 224
The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results 210
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 202
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 199
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: High white blood cell count at diagnosis is the strongest prognostic factor 199
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 195
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 190
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 181
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 173
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 170
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 169
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 163
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 161
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols 154
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial 146
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 138
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia 137
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia 130
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 127
Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia 121
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 118
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 110
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 82
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 74
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease 70
A Hematopoietic Stem Cell Transplantation Startup in Iraqi Kurdistan: Results in Thalassemia Patients and Analysis of the Methodology 64
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 55
Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome 47
Totale 5.044
Categoria #
all - tutte 19.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.322


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020122 0 0 0 0 0 0 0 0 0 64 44 14
2020/2021884 54 99 95 74 47 89 75 89 61 53 68 80
2021/2022484 51 55 66 44 23 52 15 23 35 20 42 58
2022/2023867 88 262 50 85 46 132 15 77 53 2 47 10
2023/2024516 26 16 24 60 64 129 107 26 13 6 5 40
2024/2025884 56 158 98 80 127 46 63 29 170 57 0 0
Totale 5.044